Miromatrix Medical files $200M mixed securities shelf 16:1607/0107/01/22
iSpecimen files $100M mixed securities shelf 16:0907/0107/01/22
Agile Therapeutics prices upsized 26.7M share offering at 90c per share » 09:3207/0107/01/22
Agile Therapeutics announced the pricing of its upsized public offering of an aggregate of 26,666,666 shares of its common stock together with accompanying common stock warrants, at a public offering price of $0.90 per share and accompanying warrants. Each share of common stock was sold in the offering together with a Series A-1 warrant to purchase one share of common stock at an exercise price of $0.90 per share and a Series A-2 warrant to purchase one share of common stock at an exercise price of $0.90 per share. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Offering was upsized to $24M from $20M.
Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations » 09:2907/0107/01/22
MU, FDX, CPNG, HOG, TTE, BP, FRC, STR, GRNNF, DCT, XPEV, NMTR, CMCSA, PARA, VECT, SOUN, SYM, WMT
Largest borrow rate increases among liquid names » 08:4507/0107/01/22
BYND, CSSE, SJT, BKKT, NNOX, APPH, GNUS, NKLA, MDT, PMVP
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: Beyond Meat (BYND) 77.64% +34.48, Chicken Soup for the Soul Entertainment (CSSE) 68.01% +3.10, San Juan Basin Royalty Trust (SJT) 12.66% +2.53, Bakkt Holdings (BKKT) 30.42% +2.10, Nano X Imaging (NNOX) 35.12% +1.11, AppHarvest (APPH) 73.61% +0.87, Genius Brands (GNUS) 36.96% +0.82, Nikola (NKLA) 13.30% +0.60, Medtronic (MDT) 0.73% +0.48, and PMV Pharmaceuticals (PMVP) 1.10% +0.43.
Neptune Wellness downgraded to Neutral from Buy at Alliance Global Partners » 08:3207/0107/01/22
Alliance Global Partners…
Alliance Global Partners analyst Aaron Grey downgraded Neptune Wellness Solutions to Neutral from Buy without a price target. The analyst had been looking for the company to secure some debt or credit to fund growth since the beginning of the year, but has not seen it to dote. Shareholders could be subject to further dilution if credit is not obtained or Neptune's cannabis assets are not sold, Grey tells investors in a research note. He says liquidity concerns "are too great at this time."
9 Meters Biopharma downgraded to Hold from Buy at Maxim » 08:0107/0107/01/22
Maxim analyst Jason…
Maxim analyst Jason McCarthy downgraded 9 Meters Biopharma to Hold from Buy without a price target after the company announced the Phase 2 results from its vurolenatide VIBRANT study for short bowel syndrome as well as a senior secured convertible notes facility with a single lender for up to $70M. The initial drawdown of $20M may extend 9 Meters' cash runway into Q4 of 2023, but based on the terms of the convertible notes, there is likelihood of additional dilution, McCarthy tells investors in a research note.
Talaris Therapeutics downgraded to Market Perform at SVB Securities » 16:2606/3006/30/22
SVB Securities analyst…
SVB Securities analyst Mani Foroohar downgraded Talaris Therapeutics to Market Perform from Outperform.
Fate Therapeutics appoints Brian Powl Chief Commercial Officer » 16:0406/3006/30/22
Fate Therapeutics announced that Brian T. Powl has been appointed Chief Commercial Officer. Mr. Powl brings to Fate Therapeutics extensive commercial leadership experience in hematologic malignancies and solid tumors, having previously served as the Global Commercial CAR T lead at Celgene Corporation where he oversaw the commercial development strategy of the company's CAR T-cell therapies.Mr. Powl most recently served as Senior Vice President, Commercial Development & Marketing at MEI Pharma, Inc., where he led the commercialization efforts of a late-stage small molecule program in B-cell malignancies across marketing, sales, market access and commercial operations. Prior to MEI Pharma, Mr. Powl was Vice President, Global Commercial CAR T lead at Celgene Corporation, where he oversaw a global portfolio of new cell therapy products, including the commercialization of the CD19- and BCMA-targeted CAR T-cell therapy programs. During his tenure at Celgene, Mr. Powl also held various senior level positions, including leading their flagship multiple myeloma franchise in which he led the marketing of Revlimid and Pomalyst as well as their global commercial operations group for oncology products outside the United States. Prior to Celgene, Mr. Powl held sales and marketing positions at Novartis Oncology and Centocor, Inc. Mr. Powl holds a BS in Biochemistry from the University of California, San Diego and an MBA in Healthcare
Titan Medical appoints Cary Vance as CEO » 16:0306/3006/30/22
Titan Medical announced…
Titan Medical announced that Cary Vance has been appointed as the company's president and CEO effective July 1. Vance will succeed Paul Cataford, Titan's chair of the board of directors, who has served as interim president and CEO since December 2021. Vance previously served as president and CEO at Xcath Incorporated, a privately held neurovascular robotics company.